Glucagon-like Peptide-1 analogues and delipidation of coronary atheroma in statin-treated type 2 diabetic patients with coronary artery disease: The prespecified sub-analysis of the OPTIMAL randomized clinical trial
暂无分享,去创建一个
F. Otsuka | H. Makino | T. Noguchi | Y. Asaumi | Kyoko Honda-Kohmo | T. Tamanaha | M. Tochiya | H. Matama | M. Fujino | S. Yoneda | Yoko Omura-Ohata | R. Koezuka | Kota Murai | Miki Matsuo | S. Kitahara | K. Sawada | T. Iwai | Michio Noguchi | Masaki Matsubara | Stephen J. Nicholls | Kazuhiro Nakao | Kiminori Hosoda | Satoshi Honda | Tsutomu Tomita | Yu Kataoka | S. Funabashi | Kensuke Takagi | Satoshi Yasuda
[1] F. Otsuka,et al. The effect of continuous glucose monitoring-guided glycemic control on progression of coronary atherosclerosis in type 2 diabetic patients with coronary artery disease: The OPTIMAL randomized clinical trial. , 2023, Journal of diabetes and its complications.
[2] R. Gabbay,et al. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) , 2022, Diabetologia.
[3] H. Kitahara,et al. Relation of glucose variability to vulnerable plaque formation in patients with coronary artery disease , 2022, Heart and Vessels.
[4] T. Hansen,et al. Effect of liraglutide on expression of inflammatory genes in type 2 diabetes , 2021, Scientific Reports.
[5] F. Otsuka,et al. The association between the extent of lipidic burden and delta-fractional flow reserve: analysis from coronary physiological and near-infrared spectroscopic measures. , 2021, Cardiovascular diagnosis and therapy.
[6] F. Otsuka,et al. The feasibility and limitation of coronary computed tomographic angiography imaging to identify coronary lipid-rich atheroma in vivo: Findings from near-infrared spectroscopy analysis. , 2021, Atherosclerosis.
[7] K. Duffin,et al. Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes , 2020, The Journal of clinical endocrinology and metabolism.
[8] M. Vaduganathan,et al. Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Cardiovascular Disease: A Review. , 2020, JAMA cardiology.
[9] P. K. Sharma. Atherosclerosis. , 2020, The Journal of the Association of Physicians of India.
[10] C. Mathieu,et al. 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) , 2019, Diabetes Care.
[11] K. Hosoda,et al. The efficacy of glycemic control with continuous glucose monitoring on atheroma progression: rationale and design of the Observation of Coronary Atheroma Progression under Continuous Glucose Monitoring Guidance in Patients with Type 2 Diabetes Mellitus (OPTIMAL). , 2019, Cardiovascular diagnosis and therapy.
[12] G. Filippatos,et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. , 2019, European heart journal.
[13] Jie Sun,et al. Liraglutide suppresses TNF-α-induced degradation of extracellular matrix in human chondrocytes: a therapeutic implication in osteoarthritis. , 2019, American journal of translational research.
[14] Jinghua Liu,et al. Association Between Blood Glucose Variability and the Characteristics of Vulnerable Plaque in Elderly Non-ST Segment Elevation Acute Coronary Syndrome Patients. , 2019, International heart journal.
[15] C. Janovsky,et al. Triglycerides and triglyceride-rich lipoproteins in the development and progression of atherosclerosis , 2019, Current opinion in endocrinology, diabetes, and obesity.
[16] J. Hecksher-Sørensen,et al. The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE−/− and LDLr−/− Mice by a Mechanism That Includes Inflammatory Pathways , 2018, JACC. Basic to translational science.
[17] A. Hirayama,et al. Prevalence of familial hypercholesterolemia in patients with acute coronary syndrome in Japan: Results of the EXPLORE-J study. , 2018, Atherosclerosis.
[18] D. Drucker. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. , 2018, Cell metabolism.
[19] Eyal Dassau,et al. International Consensus on Use of Continuous Glucose Monitoring , 2017, Diabetes Care.
[20] P. Libby,et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease , 2017, The New England journal of medicine.
[21] S. Martínez-Hervás,et al. The GLP-1 analogue lixisenatide decreases atherosclerosis in insulin-resistant mice by modulating macrophage phenotype , 2017, Diabetologia.
[22] H. Sugihara,et al. Effect of Glycemic Control on Chylomicron Metabolism and Correlation between Postprandial Metabolism of Plasma Glucose and Chylomicron in Patients with Type 2 Diabetes Treated with Basal-bolus Insulin Therapy with or without Vildagliptin , 2017, Journal of atherosclerosis and thrombosis.
[23] W. Koenig,et al. Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial. , 2016, JAMA.
[24] M. Shao,et al. Non-HDL Cholesterol and Triglycerides: Implications for Coronary Atheroma Progression and Clinical Events , 2016, Arteriosclerosis, thrombosis, and vascular biology.
[25] Lawrence A Leiter,et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. , 2016, The New England journal of medicine.
[26] J. Buse,et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. , 2016, The New England journal of medicine.
[27] Songtao Tang,et al. Effects of glucagon-like peptide-1 on advanced glycation endproduct-induced aortic endothelial dysfunction in streptozotocin-induced diabetic rats: possible roles of Rho kinase- and AMP kinase-mediated nuclear factor κB signaling pathways , 2016, Endocrine.
[28] P. Fitzgerald,et al. Association between blood glucose variability and coronary plaque instability in patients with acute coronary syndromes , 2015, Cardiovascular Diabetology.
[29] M. Nieuwdorp,et al. GLP1, an Important Regulator of Intestinal Lipid Metabolism. , 2015, Arteriosclerosis, thrombosis, and vascular biology.
[30] L. Lynch,et al. Glucagon-like peptide 1 analogue therapy directly modulates innate immune-mediated inflammation in individuals with type 2 diabetes mellitus , 2014, Diabetologia.
[31] B. Nordestgaard,et al. Elevated Remnant Cholesterol Causes Both Low-Grade Inflammation and Ischemic Heart Disease, Whereas Elevated Low-Density Lipoprotein Cholesterol Causes Ischemic Heart Disease Without Inflammation , 2013, Circulation.
[32] Samin K. Sharma,et al. Changes in plaque lipid content after short-term intensive versus standard statin therapy: the YELLOW trial (reduction in yellow plaque by aggressive lipid-lowering therapy). , 2013, Journal of the American College of Cardiology.
[33] B. Nordestgaard,et al. Remnant cholesterol as a causal risk factor for ischemic heart disease. , 2013, Journal of the American College of Cardiology.
[34] R. Yeh,et al. Comparison of nonculprit coronary plaque characteristics between patients with and without diabetes: a 3-vessel optical coherence tomography study. , 2012, JACC. Cardiovascular interventions.
[35] J. Danesh,et al. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies , 2010, The Lancet.
[36] R. Kawamori,et al. Inhibition of Monocyte Adhesion to Endothelial Cells and Attenuation of Atherosclerotic Lesion by a Glucagon-like Peptide-1 Receptor Agonist, Exendin-4 , 2010, Diabetes.
[37] R. Testa,et al. Oscillating Glucose Is More Deleterious to Endothelial Function and Oxidative Stress Than Mean Glucose in Normal and Type 2 Diabetic Patients , 2008, Diabetes.
[38] E. Tuzcu,et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. , 2008, JAMA.
[39] Y. Naito,et al. Short-term high glucose exposure induces monocyte-endothelial cells adhesion and transmigration by increasing VCAM-1 and MCP-1 expression in human aortic endothelial cells. , 2007, Atherosclerosis.
[40] B. Nordestgaard,et al. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. , 2007, JAMA.
[41] P. Libby. Inflammation in atherosclerosis , 2002, Nature.
[42] R. Marfella,et al. Inflammatory Cytokine Concentrations Are Acutely Increased by Hyperglycemia in Humans: Role of Oxidative Stress , 2002, Circulation.
[43] Peter Libby,et al. Atherosclerosis: the new view. , 2002, Scientific American.
[44] W. E. Sanabria,et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. , 2019, Lancet.